Acute myeloid leukemia (AML) is a complex disease with a diverse genetic landscape, leading to treatment challenges and frequent relapses. Measurable residual disease (MRD) testing has become a standard in the management of AML, utilized to detect remaining leukemia cells post-treatment and guide risk assessment and treatment decisions for better outcomes. However, monitoring MRD in AML is challenging due to its evolving nature.
In this study, the team led by Ross Levine, MD, and Wenbin Xiao, MD, PhD, at MSK demonstrates the capabilities of the Tapestri® Single-Cell MRD AML Multiomic Assay to identify relapse-related mutations missed by bulk with a limit of detection of 0.01%, and characterize the clonal architecture and distinguish pre-leukemic from leukemic subpopulations with combined single-cell DNA sequencing and immunophenotyping.
